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Increased expression of aggrecan and biglycan
mRNA in Achilles tendinopathy
A. N. Corps, A. H. N. Robinson1, T. Movin2, M. L. Costa1,
B. L. Hazleman and G. P. Riley
Objectives. To determine the expression of mRNA encoding the proteoglycans aggrecan, versican, biglycan and decorin in
mid-tendon samples of chronic painful Achilles tendinopathy and ruptured Achilles tendons, compared with normal tendons.
Methods. Total RNA isolated from frozen tendon samples (14 normal, 13 painful, 14 ruptured) was assayed by relative
quantitative reverse transcription polymerase chain reaction for aggrecan, versican, biglycan and decorin mRNA, normalized
using 18S rRNA. Differences between sample groups were tested by univariate analysis of variance with age as co-variate.
Results. In normal tendon samples expression of each of the proteoglycan mRNA decreased with increasing age. Decorin
mRNA was the most highly-expressed of the proteoglycan mRNA, while versican mRNA expression was higher (3.8-fold) than
that of aggrecan. In painful tendinopathy both aggrecan and biglycan mRNA expression increased (more than 10-fold and
5-fold, respectively) compared with normal tendon samples, but levels of versican and decorin mRNA were not signiﬁcantly
changed. In ruptured tendons the levels of aggrecan, biglycan and versican mRNA were not changed compared with normal
tendon samples, but decorin mRNA decreased markedly.
Conclusions. Increased aggrecan and biglycan mRNA expression in painful tendinopathy resembles the pattern in
ﬁbrocartilaginous regions of tendon, and may reﬂect an altered mechanical environment at the site of the lesion. Increased
aggrecan mRNA expression may underlie the increase in glycosaminoglycan observed in painful tendinopathy.
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The extracellular matrix (ECM) of tendon shows marked regional
differences in its composition, with corresponding changes in the
mRNA synthesized by the cells within the tendon [1–8]. The ECM
in tensile mid-tendon consists primarily of type I collagen, while
the predominant proteoglycan component is the small leucine-
rich proteoglycan decorin, and the principal large aggregating
proteoglycan is versican [1, 3, 4, 7]. In ﬁbrocartilaginous regions,
situated where the tendon inserts into bone or wraps around
bone, the ECM more resembles that of cartilage, with increased
expression of type II collagen and the proteoglycans aggrecan and
biglycan [2, 4–8].
Tendons such as the Achilles are subject to a spectrum of
pathological conditions, including both chronic painful ‘overuse’
injuries without overt rupture and so-called ‘spontaneous’ ruptures
without prior clinical symptoms [1, 9–11], although there may
be subclinical degeneration [9]. There is increasing evidence
supporting the view that there is a normal turnover of ECM
components in tendon, and that the balance between synthesis
and breakdown is disrupted in tendinopathy, with altered expres-
sion of ECM-active metalloproteinases [1, 12–14]. In this study,
we show that the expression pattern of the major proteoglycan
genes in chronic tendinopathy is altered towards that seen in the
ﬁbrocartilaginous regions of normal tendon.
Materials and methods
Tendon RNA samples
Achilles tendon specimens were as follows: (i) 14 normal specimens
from cadaver material, taken within 48 h of death from individuals
with no history of tendinopathy, although four samples showed
some evidence of subclinical degeneration, consistent with [9];
(ii) tissue from 13 individuals suffering painful tendinopathy for
more than 6 months, taken from the site of the lesion during
surgery and of abnormal histological appearance; (iii) tissue from
14 individuals undergoing repair of ruptured tendon, most within
48 h of the rupture occurring, trimmed from the site of the rupture.
All procedures had appropriate local ethical committee approval,
and informed patient consent. The age of the individuals from
which tissue was taken was as follows: normal tendon, range
20–97 yr, median 55 yr; painful tendinopathy, range 32–59 yr,
median 43 yr; ruptured tendon, range 25–69 yr, median 45 yr.
Specimens were transported to the laboratory in ice-cold balanced
salts solution, and dissected pieces of mid-tendon (between
10–70mg wet weight) were frozen at 70C.
Total RNA was isolated from the frozen tissue samples as
described previously [13] and was resuspended in 100l water.
The concentration of RNA was estimated using a NanoDrop
spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA; courtesy of Professor D. E. Neal’s group at the Hutchison/
MRC Research Centre, Cambridge). The majority of samples
yielded between 20 and 70 ng RNA/mg wet weight, consistent with
the low cellularity of tendon. Some of the painful tendon samples
gave higher yields, consistent with an increased cellularity [10]. The
absorbance ratio A260:A280 was 1.70 0.03 (mean S.E.M.), and
samples from each group gave well-deﬁned bands of 28S and 18S
rRNA on 1.2% (w/v) agarose gels, with no evidence of signiﬁcant
degradation. Assays of more than 60 different target mRNA on
these RNA samples have shown markedly different patterns
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(A.N.C. and G. C. Jones, data not shown), suggesting that there
is no systematic variation in mRNA quality (due to degradation)
between the tissue groups. The RNA was diluted to 1 ng/l, and
stored at 70C as aliquots that were thawed once only.
Relative quantitative reverse transcriptase polymerase
chain reaction (RT-PCR)
One-step RT-PCR was performed in a GeneAmp 5700
(Applied Biosystems). Oligonucleotide primers were obtained
from Invitrogen (Paisley, UK) and ﬂuorescein (FAM)-labelled
oligonucleotide probes were obtained from Sigma-Genosys
(Haverhill, UK). The primers and probe for versican, detecting
all variants, were described previously [14]. Primers and probes
for aggrecan, biglycan and decorin mRNA and 18S rRNA were
designed using Primer Express (Applied Biosystems). Accession
numbers, amplicons, forward primer (F), reverse primer (R) and
probe (P) sequences were as follows. Aggrecan (NM_013227; 71
base pairs (bp)): F¼CCGCTACGACGCCATCTG; R¼CCCC
CACTCCAAAGAAGTTTT; P¼TACACAGGTGAAGACTT
TGTGGACATCCCA. Biglycan (NM_001711; 105 bp): F¼
CTCAACTACCTGCGCATCTCAG; R¼GATGGCCTGGAT
TTTGTTGTG; P¼CCAAAGACCTCCCTGAGACCCTGA
ATGA. Decorin (all variants detected) (NM_001920; 71 bp):
F¼GCTGTCAATGCCATCTTCGA; R¼GGGAAGATCC
TTTGGCACTTT; P¼CCAGACCCAAATCAGAACACTGG
ACCA. 18S rRNA (M10098; 66 bp): F¼GCCGCTAGAG
GTGAAATTCTTG; R¼CATTCTTGGCAAATGCTTTCG;
P¼ACCGGCGCAAGACGGACCAG.
Each amplicon included intron–exon boundaries to prevent
ampliﬁcation of genomic DNA, no signal was produced if either
the RNA or the reverse transcriptase was omitted, and each primer
pair generated a single product of the appropriate size. BLAST
searches (http://www.ncbi.nlm.nih.gov/BLAST/) revealed no sig-
niﬁcant similarity to other sequences. In particular, since biglycan
and decorin have a high sequence similarity, their amplicons
were chosen to maximize differences, particularly at the 30 ends of
the primers. Standard curves were run in each assay, using freshly
diluted aliquots of pooled tendon tissue RNA, producing linear
plots of threshold cycle (Ct) against log(dilution), whose slope
was within 10% of the expected value, indicating similar, near-
maximum efﬁciency. This allows an approximate comparison
of the levels of different targets. For each target mRNA, all
samples of tendon tissue RNA (2 ng/well, except for 18S rRNA,
0.1 ng/well) were assayed in duplicate on the same plate. Values
for proteoglycan mRNA were normalized for 18S rRNA, using
the formula proteoglycan/18S¼ 2[Ct(18S)Ct(proteoglycan)] and cor-
rected for the different input RNA. Comparison of the expression
levels of each target mRNA between tissue sample groups was
performed using univariate analysis of variance with age as
covariate, and Bonferroni correction for multiple comparisons.
Results
The expression of mRNA encoding aggrecan, biglycan, versican
and decorin was assayed in samples of normal mid-tendon, chronic
painful tendinopathy and ruptured Achilles tendons. In samples
of normal tendon, the expression of each proteoglycan mRNA
decreased with increasing age (shown by the broken lines in
Fig. 1, A to D), the gradient of the curves corresponding to a
halving of mRNA level every 14 yr (aggrecan) to 34 yr (versican).
An analysis of the expression data, accounting for the effect of
age, is shown in Table 1. Consistent with it being the most
abundant proteoglycan in tendon, decorin mRNA was expressed
at the highest levels, more than 50-fold higher than biglycan and
versican mRNA (Table 1). Aggrecan mRNA expression was lower
(3.8-fold) than that of versican in the normal samples (Fig. 1E),
consistent with versican mRNA being the principal large proteo-
glycan expressed in tensile mid-tendon.
In samples of painful tendinopathy, both aggrecan and biglycan
mRNA showed highly signiﬁcant increases (more than 10-fold
and 5-fold, respectively) compared with normal tendon samples,
but levels of versican and decorin mRNA were not signiﬁcantly
changed (Fig. 1, Table 1). Thus, in painful tendinopathy aggrecan
mRNA was expressed at levels 6-fold higher than versican
mRNA, reversing the relative expression levels compared with
those in normal tendon (Fig. 1E). In ruptured tendons the levels
of aggrecan, biglycan and versican mRNA were unchanged
compared with normal tendon samples, but decorin mRNA
decreased markedly (Fig. 1, Table 1).
When the expression levels of the proteoglycan mRNA were
compared pairwise, each pair showed signiﬁcant correlation in
the normal tendon group (Spearman coefﬁcients (RS) between
0.70 and 0.90; P<0.01 or P<0.001 in each comparison), reﬂecting
the decrease in expression of each gene with age. Taking all three
sample groups together, none of the other proteoglycan mRNA
showed a signiﬁcant correlation with versican mRNA. However,
the expression levels of aggrecan and biglycan mRNA showed a
signiﬁcant correlation (Fig. 1F; RS¼ 0.82; P<0.001); furthermore,
these two mRNA were the only pair that showed a correlation
in the painful tendon group (RS¼ 0.86; P<0.001).
Discussion
The expression of each of the proteoglycan genes studied shows
quite a wide range in each tendon group. A major factor in this
variation is the age of the subject, each mRNA level decreasing
with age; versican mRNA shows both the slowest rate of decrease
and the smallest range of values in each group (Fig. 1). The
expression of aggrecan and biglycan mRNA in painful tendino-
pathy, and of decorin mRNA in ruptured tendons, show
signiﬁcant deviation from the normal range, and the pattern of
age dependence is disrupted (Fig. 1); we suppose that this reﬂects
a heterogeneity of these samples, for example in the severity or
duration of the painful condition.
Fibrocartilaginous regions of tendon are subject to shear or
compression in addition to tension, and increased expression of
the proteoglycans aggrecan and biglycan contributes to the
difference in physical properties compared with the tensile mid-
tendon [4, 5, 8]. Indeed, various studies have indicated that this
expression may be an adaptive response to mechanical load [5, 15].
Here, we have shown that expression of both of these genes is
up-regulated in chronic painful tendinopathy; the correlation of
their expression, within the painful group as well as the whole
group (Fig. 1F), indicates that they may be coordinately regulated.
In turn, this suggests that there may be increased compression
or shear stress within the site of the lesion, and that the cells
are responding to this altered mechanical environment, although
there may be additional cues from altered interaction of the cells
with the ECM itself. Although the increased expression of
aggrecan and biglycan mRNA may be analogous to that in the
tendon ﬁbrocartilages, it should be noted that the tendinopathy
samples do not show a complete change to a cartilaginous pattern
of gene expression. Type II collagen is highly expressed in cartilage
and in tendon ﬁbrocartilages [2, 4–8]: however, although COL2A1
mRNA was detectable by relative quantitative RT-PCR in a
greater number of the painful tendinopathy samples than of
the normals, its expression level remained 1000-fold lower than
that of type I collagen (A.N.C., data not shown), which increased
markedly in tendinopathy [14].
In painful tendinopathy, there is a marked increase in glycos-
aminoglycan (GAG) [1, 10, 16]. This could be due to increased
expression or glycosylation of proteoglycans, or to decreased
expression or activity of degradative enzymes, including aggreca-
nases of the ADAMTS family, which have been shown to be active
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in bovine tendon [3, 17]. In an earlier study, using a subset of
the present sample set and normalizing to GAPDH mRNA rather
than 18S rRNA, we reported a small but signiﬁcant decrease in
versican mRNA in both painful and ruptured tendon samples
[14]: we concluded that the observed increase in GAG (3.5-fold)
in these samples was unlikely to be due to increased versican
expression [14]. With the present enlarged sample set, comparison
with 18S rRNA has indicated that GAPDH mRNA is signiﬁcantly
elevated with respect to total RNA, particularly in ruptured tendon
samples (A.N.C., data not shown); this effect, due possibly to an
up-regulation of GAPDH expression under the hypoxic conditions
found in ruptured tendons [9], renders GAPDH a poor reference
gene. Normalization to 18S rRNA (this study) indicates that
versican mRNA levels in painful and ruptured tendons are not
signiﬁcantly different from those in normal tissue. However,
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FIG. 1. Expression of proteoglycan mRNA in normal tendons, painful tendinopathy and ruptured tendons. (A) aggrecan mRNA,
(B) biglycan mRNA, (C) versican mRNA and (D) decorin mRNA were assayed and normalized for 18S rRNA. Each point represents
a separate sample, plotted against the age of the subject: normal tendons (g), painful tendinopathy (i) and ruptured tendons (). The
broken lines show the exponential decrease of the mRNA in normal tendons with age. (E) Aggrecan:versican ratios for the samples
shown in (A) and (C), plotted against clinical group and showing the median values. ***P<0.001 for painful tendons compared with
normal group. yyyP<0.001 for ruptured tendons compared with painful group. (F) Correlation of aggrecan and biglycan mRNA
expression in tendon samples shown in (A) and (B): Spearman co-efﬁcient¼ 0.82; P<0.001.
TABLE 1. Expression of proteoglycan mRNA in normal tendons, painful
tendinopathy and ruptured tendons
mRNA/18S rRNA (106)
mRNA Normal Painful Ruptured
Aggrecan 2.3 34.4*** 2.4yyy
Biglycan 9.3 53.9*** 16.8yyy
Versican 8.8 5.3 13.5y
Decorin 535 393 69***,yy
The data shown in Fig. 1 were analysed using univariate analysis of
variance with age as covariate. The estimated marginal means (evaluated
at age 49 yr) are shown. ***P<0.001 for painful or ruptured tendons
compared with normal group. y, yy, yyyP<0.05, 0.01 or 0.001, respec-
tively, for ruptured tendons compared with the painful group.
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irrespective of the method of normalization of the mRNA data,
our present results indicate that aggrecan mRNA increases
from 3.8-fold lower than versican mRNA in normal mid-tendon
to 6-fold higher than versican mRNA in painful tendinopathy:
given that aggrecan is more highly glycosylated than versican
[18], this change in the predominant large proteoglycan
mRNA provides a very likely basis for the increased GAG
observed in tendinopathy. This conclusion may be tested by an
analysis of the proteoglycan proteins and their breakdown
products in the tendon samples, analogous to work done in bovine
tendons [3, 17].
Finally, each of the proteoglycan genes shows a signiﬁcant
difference in expression level between painful and ruptured
tendons, emphasizing that these are different conditions. In
ruptured tendon, there is loss of mechanical loading, which may
explain the lack of an increase of aggrecan or biglycan mRNA
levels similar to that observed in chronic painful tendinopathy.
Instead, in ruptured tendons there is a marked decrease in the
expression levels of decorin mRNA, the most highly-expressed
proteoglycan mRNA. We suppose that this decrease may
reﬂect the activity of a tendon that is undergoing a repair
response, but the underlying cellular regulation remains to be
determined.
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Key messages
 Increased aggrecan and biglycan mRNA
expression in painful tendinopathy
may reﬂect altered mechanical stress,
as observed in tendon ﬁbrocartilages,
and may underlie the increase in
glycosaminoglycan that occurs in
tendinopathy.
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